Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
DR. REDDYS LAB | GLENMARK PHARMA | DR. REDDYS LAB/ GLENMARK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.3 | 14.3 | 240.0% | View Chart |
P/BV | x | 4.7 | 2.4 | 199.9% | View Chart |
Dividend Yield | % | 0.6 | 0.4 | 131.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. REDDYS LAB Mar-20 |
GLENMARK PHARMA Mar-19 |
DR. REDDYS LAB/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,363 | 712 | 472.6% | |
Low | Rs | 2,352 | 484 | 486.4% | |
Sales per share (Unadj.) | Rs | 1,054.2 | 349.6 | 301.5% | |
Earnings per share (Unadj.) | Rs | 121.9 | 32.8 | 371.9% | |
Cash flow per share (Unadj.) | Rs | 190.2 | 44.3 | 429.1% | |
Dividends per share (Unadj.) | Rs | 25.00 | 2.00 | 1,250.0% | |
Dividend yield (eoy) | % | 0.9 | 0.3 | 261.4% | |
Book value per share (Unadj.) | Rs | 938.7 | 198.6 | 472.6% | |
Shares outstanding (eoy) | m | 166.17 | 282.17 | 58.9% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.7 | 1.7 | 158.6% | |
Avg P/E ratio | x | 23.4 | 18.2 | 128.6% | |
P/CF ratio (eoy) | x | 15.0 | 13.5 | 111.4% | |
Price / Book Value ratio | x | 3.0 | 3.0 | 101.2% | |
Dividend payout | % | 20.5 | 6.1 | 336.1% | |
Avg Mkt Cap | Rs m | 474,831 | 168,625 | 281.6% | |
No. of employees | `000 | 21.7 | 12.0 | 179.9% | |
Total wages/salary | Rs m | 33,802 | 20,561 | 164.4% | |
Avg. sales/employee | Rs Th | 8,091.0 | 8,196.0 | 98.7% | |
Avg. wages/employee | Rs Th | 1,561.3 | 1,708.1 | 91.4% | |
Avg. net profit/employee | Rs Th | 935.8 | 768.5 | 121.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 175,170 | 98,655 | 177.6% | |
Other income | Rs m | 6,206 | 2,081 | 298.2% | |
Total revenues | Rs m | 181,376 | 100,736 | 180.1% | |
Gross profit | Rs m | 24,421 | 15,858 | 154.0% | |
Depreciation | Rs m | 11,348 | 3,259 | 348.2% | |
Interest | Rs m | 983 | 3,346 | 29.4% | |
Profit before tax | Rs m | 18,296 | 11,335 | 161.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 561 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
Tax | Rs m | -1,403 | 3,756 | -37.3% | |
Profit after tax | Rs m | 20,260 | 9,250 | 219.0% | |
Gross profit margin | % | 13.9 | 16.1 | 86.7% | |
Effective tax rate | % | -7.7 | 33.1 | -23.1% | |
Net profit margin | % | 11.6 | 9.4 | 123.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 125,991 | 66,968 | 188.1% | |
Current liabilities | Rs m | 72,141 | 40,211 | 179.4% | |
Net working cap to sales | % | 30.7 | 27.1 | 113.3% | |
Current ratio | x | 1.7 | 1.7 | 104.9% | |
Inventory Days | Days | 73 | 83 | 87.7% | |
Debtors Days | Days | 105 | 81 | 129.0% | |
Net fixed assets | Rs m | 83,854 | 33,322 | 251.6% | |
Share capital | Rs m | 831 | 282 | 294.5% | |
"Free" reserves | Rs m | 155,157 | 55,770 | 278.2% | |
Net worth | Rs m | 155,988 | 56,052 | 278.3% | |
Long term debt | Rs m | 1,304 | 35,738 | 3.6% | |
Total assets | Rs m | 232,253 | 132,888 | 174.8% | |
Interest coverage | x | 19.6 | 4.4 | 447.0% | |
Debt to equity ratio | x | 0 | 0.6 | 1.3% | |
Sales to assets ratio | x | 0.8 | 0.7 | 101.6% | |
Return on assets | % | 9.1 | 9.5 | 96.5% | |
Return on equity | % | 13.0 | 16.5 | 78.7% | |
Return on capital | % | 12.6 | 17.8 | 70.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 84,193 | 62,998 | 133.6% | |
Fx outflow | Rs m | 39,616 | 22,859 | 173.3% | |
Net fx | Rs m | 44,577 | 40,140 | 111.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 29,841 | 13,242 | 225.4% | |
From Investments | Rs m | -4,923 | -6,990 | 70.4% | |
From Financial Activity | Rs m | -25,159 | -7,387 | 340.6% | |
Net Cashflow | Rs m | -266 | -2,971 | 9.0% |
Indian Promoters | % | 25.5 | 48.3 | 52.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 5.4 | 6.9 | 78.3% | |
FIIs | % | 35.3 | 34.4 | 102.6% | |
ADR/GDR | % | 18.5 | 0.0 | - | |
Free float | % | 15.3 | 10.5 | 145.7% | |
Shareholders | 75,885 | 56,727 | 133.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. REDDYS LAB With: JUBILANT LIFE SCIENCES PANACEA BIOTECH WOCKHARDT ABBOTT INDIA FRESENIUS KABI ONCO.
Compare DR. REDDYS LAB With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More